EORTC Genito-Urinary Cancers Group

Open studyStudy to be openClosed study
1211
Phase II randomized comparative trial of TAK-700 (orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.
30073
Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma.
22043
Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage post-operative external radiotherapy alone in pT3a-b R0-1 cNOMO/pT2R1 cN0M0, Gleason score 5-10 prostatic carcinoma. A phase III study.
30072
A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
30061
Phase I study of cisplatin, gemcitabine (+ paclitaxel) and lapatinib as first line treatment in advanced/metastatic urothelial cancer
30021
Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC
30992
Phase II study of Irinotecan (CPT 11) and Cisplatin (CDDP) in metastatic or locally advanced penile carcinoma.
30012
A Randomised Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs Interferon-alpha Alone in Patients with Advanced Renal Cell Carcinoma.
30004
Chemoresection with 4 weekly intravesical instillations of mitomycin C versus transurethral resection (TUR) followed by one single immediate instillation of mitomycin C in single, small, papillary stage Ta, T1 bladder tumors : A prospective randomized phase III trial
15011
An international field of the reliability and validity of the QLQ-C30 and a disease-specific questionnaire module (QLQ-PR25) for assessing quality of life of patients with prostate cancer.
30994
Randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder
30001
Radical Prostatectomy for Locally Advanced Prostate Cancer. A Feasibility Study.
16006
Open label phase II of MEN-10755 administered every 3 weeks in patients with progressive hormone refractory prostate cancer
30993
A randomized phase II trial of sequential chemo-immunotherapy versus immunotherapy alone in carcinoma in situ of the urinary bladder.
30987
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and cisplatin/gemcitabine in patients with metastatic or locally advanced urothelial cancer without prior systemic therapy.
30986
Randomized phase II/III study assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in previously untreated patients with advanced urothelial cancer ineligible for Cisplatin based chemotherapy.
30991
Randomized phase III step-up study on initial antiandrogen monotherapy in comparison with watchful waiting in asymptomatic T1-3 any G (any Gleason) N0 or NxM0 prostate cancer patients without local treatment with curative intent.
16997
EORTC 16997 : A phase II study of SCH66336 (Farnesyl Protein Transferase Inhibitor) in combination with Gemcitabine as second line treatment in patients with advanced / metastatic urothelial tract tumor.
30974
A ranomized phase III study of sequential high-dose Cisplatinum/Etoposide/Ifosfamide plus stem cell support versus BEP in patients with poor prognosis Germ Cell Cancer
30985
Intermittent androgen deprivation in patients with stage D2 prostate cancer-Phase III
30983
Randomized phase II/III study of Taxol-BEP versus BEP in patients with intermediate prognosis germ cell cancer
30971
A feasibility study of thorough transurethral resection (TURB) and escalated dose M-VAC Chemotherapy as primary treatment of T2-T3a, N0-Nx, M0, transitional cell carcinoma of the bladder, with the intention of bladder preservation.
30972
RANDOMIZED PHASE III STUDY OF JM-216 ORAL PLATINUM PLUS PREDNISONE OR PREDNISONE ALONE IN PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER
30982
Carboplatin in the adjuvant treatment of stage I Seminoma
30955
Phase III adjuvant trial:Interleukin-2, Interferon-alpha and 5-Fluorouracil for patients with high risk of relapse after surgical treatment for RCC
22961
Long term adjuvant hormonal treatment with LHRH analogue versus no further treatment in locally advanced prostatic carcinoma treated by external irradiation and a six months combined androgen blockade - A phase III study. (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Genito-Urinary Tract Cancer Cooperative Group)
30962
Comparative study of intravesical BCG standard dose long-term maintenance versus BCG 1/3 dose long-term maintenance versus BCG standard dose short-term maintenance versus BCG 1/3 dose short-term maintenance in intermediate and high risk Ta- T1 Papillary Carcinoma of the Urinary Bladder.
30948
A Phase II trial of C-BOP/BEP intensive induction chemotherapy for intermediate and poor prognosis metastatic germ cell tumors.
30943
Randomized phase III trial of immediate versus deferred hormonal therapy in patients with elevated PSA after definitive treatment for localised prostate cancer
30954
Intermittent maximal androgen blockade in patients with metastatic prostate cancer : Feasibility study.
30951
Randomized phase II trial of Interferon alpha-2a with and without 13-cis Retinoic Acid in patients with progressive metastatic renal cell carcinoma Amendment protocol: Extension to a randomized phase III trial
30952
Quarter dose BCG on a papillary superficial bladder cancer. A phase II study on a marker lesion
30944
Randomized phase II trial assessing Estramustine and Vinblastine combination chemotherapy vs. Estramustine alone in patients with hormone escaped progressive metastatic prostate cancer
30942
A randomised Prospective Comparison of Two Schedules of Radiotherapy for Stage 1 Seminoma Testis Following Orchidectomy
30947
A randomized comparison of nephrectomy followed by Interferon Alpha 2-b (Intron-A) vs Interferon Alpha 2-b (Intron-A) alone in patients with advanced renal cell carcinoma. Phase III
30941
A randomized phase III study of 3 BEP versus 3 BEP-1 EP, and the 5-day schedule versus 3 days per cycle in good prognosis germ cell cancer
30932
Phase II study of 5-fluorouracil, Cisplatin and Interferon alpha in second line in advanced transitional cell cancer of the urothelial tract
30931
Phase II study of loboplatin in advanced urothelial tract tumors
30924
Randomized phase II / III study of high dose intensity M-VAC chemotherapy + G-CSF versus classic M-VAC in advanced urothelial tract tumors
30906
Phase III study to compare the efficacy of intravesical instillations of BCG versus Epirubicin in carcinoma in situ of the bladder
30923
Phase II trial of the efficacy and safety of roquinimex (linomide) in the treatment of renal cell carcinoma
22911
Phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Genito-Urinary Tract Cancer Cooperative Group)
30921
A prospective multicenter randomized study comparing Strontium89 Chloride and palliative local field radiotherapy in patients with hormonal escaped advanced prostatic cancer
30904
A Prospective Randomized Ohase III study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma
30911
Phase III trial of intravesical instillation of Epirubicin, BCG or BCG + INH in intermediate and high risk pTa-pT1 papillary carcinoma of the urinary bladder
30903
Phase III trial of Flutamide versus Prednisone in hormone resistant metastatic prostate cancer
30905
Phase II trial of the efficacy and safety of linomide in the treatment of renal cell carcinoma
30896
Phase III study of BEP versus CEB in the management of good prognosis metastatic testicular (and extragonadal) teratoma (MRC/EORTC Collaborative Study)
30901
A RANDOMIZED PHASE III TO COMPARE TUR AND YAG-LASER FOLLOWED BY INTRAVESICAL CHEMOPROPHYLAXIS WITH Epirubicin in SINGLE RECURRENT, MULTIPLE PRIMARY OR RECURRENT Ta-T1 TCC OF THE BLADDER
30902
Phase II study of R75251 in patients with progressive, measurable, metastatic prostate cancer
30895
Phase III study of BEP versus BOP/VIP in the management of poor prognosis metastatic testicular and extragonadal teratoma (MRC/EORTC Collaborative Study)
30897
Phase II study of Mitomycin C and intravesical immunotherapy with BCG-RIVM in recurrent superficial transitional cell carninoma of the bladder
30891
Phase III study comparing early versus delayed orchidectomy, or early versus delayed treatment with a depot LHRH analogue (Buserelin) respectively, in patients with asymptomatic non metastatic prostate cancer T0-4 N0-2 M0
30893
Phase III study comparing orchidectomy and orchidectomy + Mitomycin C in patients with metastatic prostate cancer with poor prognostic factors
30892
Phase III study comparing endocrine treatment with Flutamide or Cyproterone acetate in patients with painless metastatic prostate cancer with favorable prognostic factors
30894
Phase III study of primary chemotherapy (CMV) in T2G3, T3 and T4a, NO-X, M0 transitional cell carcinoma of the bladder (MRC/EORTC Collaborative Study)
30886
Phase II protocol to study mitomycin C in patients with advanced transitional cell carcinoma of the urinary tract resistant to or ineligible for first line chemotherapy
30884
Phase II protocol for the study of high dose Epirubicin in patients with progressive measurable metastatic prostate cancer
30883
Phase II study of high dose epirubicin in patients with progressive measurable metastatic non seminomatous germ cell tumours, including extragonadal tumours. (Jointly with the EORTC Early Clinical trials Cooperative Group - Protocol 16881)
30885
Randomized phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma
30882
Phase II study of vinblastine in patients with progressive measurable matastatic renal cell carcinoma
30881
Phase III trial of the investigation of the potentially curative value of lymphadenectomy in conjunction with radical nephrectomy for non-metastatic renal cell carcinoma
30874
Phase II study of cisplatin combination chemotherapy in high risk metastatic seminoma
30869
Phase II - III prospective randomized study to assess the effect of epirubicin in multiple bladder cancer
30873
A randomized phase III study of BEP (bleomycin, etoposide (VP-16), cisplatin) versus VIP (VP-16, ifosfamide, cisplatin) in intermediate risk patients with disseminated non-seminomatous testicular cancer
30872
PHASE II TRIAL OF TCNU IN PROGRESSIVE MEASURABLE METASTATIC RENAL CANCER -
22863
Phase III randomized clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy plus LHRH analogue (Jointly with the EORTC Genito-Urinary Cancers Group)
30871
Phase II Chemotherapy with 5-Aza-2'-deoxycytidine in Patients with Nonseminomatous Testicular or Extragonadal Germ Cell Tumors That Are Progressive, Measurable, and Metastatic (Summary Last Modified 05/88)
30868
Randomized phase II study with (A) methotrexate, cisplatin and (B) vinblastine, methotrexate and cisplatin in patients with advanced transitional cell carcinoma of the urinary tract
30861
Phase II trial of intravesical instillation of BCG in carcinoma in situ of the urinary bladder
30864
Phase II chemoresection study of mitomycin C with a marker lesion followed by a phase III study randomizing between maintenance and no maintenance in multiple TaT1 bladder cancer
30865
A randomized phase III study comparing estracyt and mitomycin-C in hormone escaped advanced prostatic cancer
30863
Phase III prospective randomized trial for the study of TUR + a single intravesical instillation of Epirubicin versus TUR alone in single, primary or recurrent, Ta/T1 papillary carcinoma of the bladder.
30866
PHASE II STUDY OF MITOZOLOMIDE IN ADVANCED RENAL CANCER
30867
PHASE II STUDY OF Epirubicin IN ADVANCED TCC OF THE URINARY TRACT FOR PATIENTS RESISTANT TO OR INELIGIBLE FOR FIRST LINE CHEMOTHERAPY
30847
Phase II protocol to study management of stage I non-seminomatous testicular cancer with unilateral orchidectomy alone
30851
Phase II trial of Cisplatin and methotrexate in T3-4 N0-X M0 transitional cell carcinoma of the bladder
30853
Phase III protocol for a randomized prospective study of the treatment of patients with metastatic prostatic cancer to compare the therapeutic effect of orchidectomy versus LHRH-analogue depot preparation supplemented by an antiandrogen
30846
Phase III trial of endocrine treatment versus delayed endocrine treatment for patients with pN1-3M0 carcinoma of the prostate
30852
PHASE II STUDY OF Methotrexate IN PROGRESSIVE MEASURABLE PROSTATE CANCER
30843
Phase III trial of the treatment of patients with metastatic prostatic cancer to compare the therapeutic effect of orchidectomy versus LHRH-analogue supplemented by an anti-androgen
30824
Phase III trial for induction chemotherapy regimens (PVB-BEP-EP) in non pretreated patients stratified for high versus low volume metastases of non seminomatous testicular cancer
30795
EORTC PROTOCOL FOR REMISSION INDUCTION CHEMOTHERAPY WITH CIS-DIAMMINE-DICHLORO- PLATINUM, VINBLASTINE AND BLEOMYCIN IN PATIENTS WITH DISSEMINATED TESTICULAR NON-SEMINOMAS, RANDOMIZING FOR 75% VBL VERSUS 100% VBL.
1329
Randomized phase 2-3 study of nab-Paclitaxel plus Gemcitabine versus Carboplatin plus Gemcitabine as front-line therapy for patients with advanced urothelial cancer who are ineligible to cisplatin.
30741
Cancer of the prostate (stage III and IV) : natural history of patients with prostatic adenocarcinoma
30742
Cancer of the prostate (stage III and IV) : use of DES in untreated patients with advanced prostatic adenocarcinoma
30763
Phase II study of procarbazine and adriamycin in the treatment of hormone resistant prostatic cancer patients
30764
Comparison of adriamycin, cyclophosphamide, and adriamycin + 5-fluorouracil in patients with advanced bladder carcinoma
30831
Phase III trial of mitomycin C in primary and recurrent Ta-T1 papillary carcinoma of the bladder randomized between immediate vs delayed administration and maintenance vs no maintenance treatment
30832
Phase III trial of adriamycin in primary and recurrent Ta-T1 papillary carcinoma of the bladder randomized between immediate vs delayed administration and maintenance vs no maintenance treatment
30835
Phase II trial of human lymphoblastoid interferon (HUIFNa) in patients with differentiated teratoma, which develops post-chemotherapy and is not amenable to surgery
30836
Phase II trial of 4-deoxydoxorubicin in advanced renal cancer
30751
Phase III trial of thiotepa, versus VM26, versus no tretament in TI bladder cancer
30761
Phase III trial of cyproterone acetate versus medroxyprogesterone acetate versus DES in T3-T4 advanced prostatic cancer
30762
Phase III trial of estracyt versus stilboestrol in T3-T4 advanced prostatic cancer
30781
Doubled blind phase III trial of pyridoxine versus placebo in T1 Nx Mx and T1 No Mo transitional cell tumors of the bladder, after transurethral resection
30782
Phase III trial of thiotepa versus adriamycin versus cis-platinum in T1 papillary carcinoma of the bladder after transurethral resection
30784
Phase III trial of adriamycin plus 5-FU versus no treatment in patients with T3, Mo bladder tumors treated primarily by 1500 rads flash and radical cystectomy
30791
Phase III trial of adriamycin versus epodyl versus no treatment in primary and recurrent Ta and T1 papillary carcinoma of the bladder after transurethal resection
30796
E.O.R.T.C. STUDY COMPARING REMISSION MAINTENANCE CHEMOTHERAPY VERSUS NO MAINTENANCE THERAPY IN TESTICULAR NON-SEMINOMAS AFTER ACHIEVEMENT OF COMPLETE REMISSION BY INDUCTION CHEMOTHERAPY WITH CIS-DIAMMINE-DICHLORO-PLATINUM, VINBLASTINE, AND BLEOMYCIN.
30797
Phase II trial of vincristine in advanced bladder cancer
30799
Phase II trial of vindesine in advanced prostatic carcinoma
30801
Phase II trial of methyl-GAG in advanced renal carcinoma
30802
Phase II trial of cisplatin plus VM26 in advanced transitional cell carcinoma of the urinary tract
30804
Phase II trial of mitomycin-C in advanced prostatic cancer
30805
Phase III trial of bilateral orchidectomy versus bilateral orchidectomy plus CPA vs stilboestrol in metastatic prostatic cancer
30811
Phase II trial of vindesine in advanced renal cell cancer
30841
Phase II trial of weekly low dose 4'epi-adriamycin in patients with advanced prostatic carcinoma
30842
Phase II trial of combination of cisplatin and methotrexate in patients with advanced transitional cell carcinoma of the unitary tract
30844
Phase II trial of TGU in patients with advanced transitional cell carcinoma of the unitary tract
30845
Phase III trial of BCG-RIV vs mitomycin-C in primary and recurrent Ta-T1 papillary carcinoma and primary carcinoma in situ of the urinary bladder
30806
Phase II trial of embolization of renal cell carcinoma and subsequent nephrectomy in patients with metastatic disease
30821
Phase II trial of cisplatin + methotrexate in advanced transitional cell carcinoma of the urinary tract
30822
Phase II trial of mitoxantrone in advanced renal cell cancer
30823
Phase II trial of mitoxantrone in advanced bladder cancer
30752BB
Phase II in Bladder Cancer: VM 26, Adriamycin
1201
A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-na´ve prostate cancer

Back to Group-list